Revolution Medicines Inc (RVMD) - News Archive

for CSIMarket.com Revolution Medicines, Inc., a late-stage clinical oncology company based in Redwood City, California, recently reported its financial results for the third quarter of 2025 and provided significant upda...

Metastatic pancreatic ductal adenocarcinoma (mPDAC) remains one of the most challenging malignancies to treat, often associated with poor prognosis and limited therapeutic options. Revolution Medicines Inc. has recently...

As markets across the globe brace for a week saturated with significant earnings reports and consequential economic data, U.S. stocks commenced the week confidently in the green on April 28, 2025.

Revolution Medicines, Inc. Announces Successful Completion of Upsized Public OfferingIn a significant development for Revolution Medicines, Inc. (NASDAQ: RVMD), the company recently announced the successful closing of a...

Revolution Medicines: A Powerful Upsized Offering Set to Fuel GrowthRevolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company dedicated to developing cutting-edge treatments for RAS-addicted cancers,...

In a bold step towards accelerating its mission to revolutionize cancer therapy, Redwood City-based Revolution Medicines Inc. (Nasdaq: RVMD) announced on December 2, 2024, its decision to commence an ambitious underwrit...

Revolution Medicines: Pioneering Advancements in RAS(ON) Inhibitor Therapy and Financial StabilityIn the relentless pursuit of groundbreaking therapies for cancer, Revolution Medicines has once again positioned itself a...

Revolution Medicines, a leading biotechnology company at the forefront of cancer research, has recently announced a groundbreaking discovery in the field of oncology. The company s publication and presentation on their...

Revolution Medicines Announces Groundbreaking Discovery and Preclinical Profile of New Class of RAS(ON) Multi-Selective Inhibitors with Unprecedented Anti-Tumor Activity in RAS-Mutant Pancreatic Cancer ModelsRevolution...